The FDA has approved risperidone once-monthly, extended-release injectable suspension for maintenance treatment of bipolar I ...

The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release injectable suspension) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance ...

The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment for bipolar I disorder, ...

This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...

Purposeful prescribing is the idea of making thoughtful, patient-centred decisions about medication – choices that reflect ...

Nearly 5 million Americans navigate the complex challenges of bipolar I disorder daily, facing dramatic shifts between manic highs and depressive lows that can derail careers, relationships and ...

When Natasha Tracy was 19, a psychiatrist diagnosed her with minor depression. “I knew this was wrong,” Tracy says. “He hadn’t listened to me. I was suffering from severe, suicidal depression.” In ...

While borderline personality disorder and bipolar disorder share common symptoms like reckless behavior, there are a few key ...

People living with bipolar disorder face stigma and treatment challenges. Despite these barriers, it’s possible to live a full and productive life with the condition. Four people share their stories.